Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Completed 46Terminated 7Recruiting 4Active not recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 313INDUSTRY 34OTHER_GOV 7NIH 6NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Dermatologic 1Breast 1

Conditions

Breast Neoplasms 18Prostatic Neoplasms 15Neoplasms 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Melanoma 9Pancreatic Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Hematologic Neoplasms 4Brain Neoplasms 4Teratoma 3Smoldering Multiple Myeloma 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms, Germ Cell and Embryonal 3Neoplasm Metastasis 3Malignant Solid Neoplasm 3HIV Infections 3Fallopian Tube Neoplasms 3Colonic Neoplasms 3

Interventions

encorafenib 1binimetinib 1Watchful Waiting 1Radiotherapy 1Radiosurgery 1Platelet Count 1Observation 1Nivolumab 1Memantine 1Ipilimumab 1Carvedilol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × NETWORK × Brain Neoplasms × Clear all
NCT03550391 2026-05-12

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Canadian Cancer Trials Group

Phase 3 Recruiting
206 enrolled
CNS

Brain Neoplasms

NCT05049148 2026-01-05

Platon

Fondation Ophtalmologique Adolphe de Rothschild

Phase NA Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioma, Inflammation

NCT03418961 2025-10-08

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

SWOG Cancer Research Network

Phase 3 Recruiting
491 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Cardiotoxicity

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 2 Recruiting
112 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡